» Articles » PMID: 11373000

The Detection of Psilocin in Human Urine

Overview
Journal J Forensic Sci
Specialty Forensic Sciences
Date 2001 May 25
PMID 11373000
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmacokinetic studies of psilocybin in humans have shown the rapid dephosphorylation of psilocybin to psilocin with further conversion to 4-hydroxy-tryptophole (4HT) and 4-hydroxyindole-3-acetic acid (4HIAA) in plasma. Our study shows that psilocin also undergoes conjugation and can be found in the urine as the psilocin-glucuronide conjugate. Recoveries after enzymatic hydrolysis of the urine with beta-glucuronidase (Helix Pomatia or E. Coli) when compared to non-hydrolyzed urine confirmed the presence of the glucuronide. Detection of psilocin from hydrolyzed and extracted samples was optimized for GC/MS by derivatization with MSTFA. The method developed allows for the detection of psilocin in urine with a limit of quantitation of 10 ng/mL, based on 5 mL of spiked urine. Using this method, our laboratory has confirmed the presence of psilocin in 6 out of 8 urine samples, with concentrations ranging from 10 ng/mL to greater than 200 ng/mL. Before implementation of the hydrolysis and derivatization steps, our limit of detection was 200 ng/mL, based on spiked urine standards. No case samples were positive without hydrolysis and derivatization.

Citing Articles

Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis.

Otto M, van der Heijden K, Schoones J, van Esdonk M, Borghans L, Jacobs G Clin Pharmacokinet. 2025; 64(1):53-66.

PMID: 39812743 PMC: 11762572. DOI: 10.1007/s40262-024-01454-4.


and metabolism of psilocybin's active metabolite psilocin.

Thomann J, Kolaczynska K, Stoeckmann O, Rudin D, Vizeli P, Hoener M Front Pharmacol. 2024; 15:1391689.

PMID: 38741590 PMC: 11089204. DOI: 10.3389/fphar.2024.1391689.


Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.

Shah F, Shehzadi S, Akram F, Ul Haq I, Javed B, Sabir S Mol Biotechnol. 2023; 67(1):36-53.

PMID: 38117395 DOI: 10.1007/s12033-023-00994-7.


Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?.

Coppola M, Bevione F, Mondola R J Xenobiot. 2022; 12(1):41-52.

PMID: 35225956 PMC: 8883979. DOI: 10.3390/jox12010004.


Recreational use, analysis and toxicity of tryptamines.

Tittarelli R, Mannocchi G, Pantano F, Romolo F Curr Neuropharmacol. 2015; 13(1):26-46.

PMID: 26074742 PMC: 4462041. DOI: 10.2174/1570159X13666141210222409.